Clinical Perspectives: Risk Factors and Patient Characteristics Associated with cGVHD

Clinical Prevalence and Risk Factors

The panel discussed the frequency of cGVHD in clinical practice:

• Common risk factors include HLA disparity, donor characteristics, and GVHD prophylaxis regimen
• Post-transplant cyclophosphamide has reduced overall incidence of cGVHD, though severity remains similar when it does occur
• The panel still quotes patients approximately 50% risk of developing cGVHD

Most common manifestations in practice are:

• Eyes, mouth, and skin (consensus among all panelists)
• Ocular GVHD may be underdiagnosed; at Fred Hutch, patients receive specialized ophthalmologic evaluation at day 80-90 departure workup, capturing subclinical cases